Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
NEW YORK (AP) — Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease.
Janssen-Cilag International will market the drug under the name Vokanamet. It is intended to treat type 2 diabetes, in which the body does not use insulin efficiently.
The U.S. Food and Drug Administration approved Invokana in March 2013. European Union authorities followed suit in November.
Shares of Johnson & Johnson lost 19 cents to $99.77 in midday trading.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
